The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-01 and is reviewed periodically as new material appears.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Regulations vary, but low concentrations, such as 5%, are widely available. Concentrated solutions of H2O2 react violently with organic materials. While concentrations up to 35% produce only "white" oxygen bubbles in the skin (and some biting pain) that disappear with the blood within 30–45 minutes, concentrations of 98% dissolve paper. However, concentrations as low as 3% can be dangerous for the eye because of oxygen evolution within the eye. When hydrogen peroxide is used at moderate to high concentrations in organic laboratories, the associated hazards include:
Conservative options include pelvic floor muscle strengthening exercises, and pessaries. Pelvic floor muscle training (PFMT), also known as Kegel exercise, has been found to improve the bulk and urinary symptoms associated with pelvic organ prolapse and improve quality of life when performed consistently and correctly. Pessaries are a mechanical treatment that supports the vagina and elevates the prolapsed uterus to its anatomically correct position. Pessaries are frequently offered as a first-line management option for uterine prolapse, especially amongst people who cannot or do not wish to undergo surgery, due to their affordability and low-risk profile compared to more invasive procedures. When properly fitted, pessaries have been found to improve bulk and pressure symptoms associated with prolapse and improve quality of life measures.
It can do this by abstracting a proton with its basic nitrogen to make a positively charged intermediate and then use another molecule, a buffer, to extract the proton from its acidic nitrogen. In carbonic anhydrases, a histidine proton shuttle is utilized to rapidly shuttle protons away from a zinc-bound water molecule to quickly regenerate the active form of the enzyme. In helices E and F of hemoglobin, histidine influences binding of dioxygen as well as carbon monoxide. This interaction enhances the affinity of Fe(II) for O2 but destabilizes the binding of CO, which binds only 200 times stronger in hemoglobin, compared to 20,000 times stronger in free heme. The tautomerism and acid-base properties of the imidazole side chain has been characterized by 15N NMR spectroscopy. The two 15N chemical shifts are similar (about 200 ppm, relative to nitric acid on the sigma scale, on which increased shielding corresponds to increased chemical shift). NMR spectral measurements shows that the chemical shift of N1-H drops slightly, whereas the chemical shift of N3-H drops considerably (about 190 vs. 145 ppm). This change indicates that the N1-H tautomer is preferred, possibly due to hydrogen bonding to the neighboring ammonium. The shielding at N3 is substantially reduced due to the second-order paramagnetic effect, which involves a symmetry-allowed interaction between the nitrogen lone pair and the excited π* states of the aromatic ring. At pH > 9, the chemical shifts of N1 and N3 are approximately 185 and 170 ppm.
== Mechanism of action == Like other enediynes, kedarcidin chromophore comprises a core structure that forms destructive free radicals, as well as appendages that deliver this "warhead" to its DNA target. Thus, the general mechanism by which kedarcidin chromophore damages DNA is known; however, the details of this process—particularly the necessity of nucleophilic activation—have been disputed.
==== Carbohydrates ==== Felines are natural carnivores and do not intentionally consume large quantities of carbohydrates. The domestic cat's liver has adapted to the lack of carbohydrates in the diet by using amino acids to produce glucose, which fuels the brain and other tissues. Studies have shown that carbohydrate digestion in young kittens is much less effective than that of a mature feline with a developed gastrointestinal tract. Highly digestible carbohydrates found in commercial kitten food provide additional energy and fiber to stimulate the immature gut tissue. Soluble fiber such as beet pulp is commonly used as a stool hardener and has been shown to strengthen intestinal muscles and thicken the gut mucosal layer, helping to prevent diarrhea.
Sources: en.wikipedia.org
A geroprotector aims to affect the root cause of aging and age-related diseases, and thus prolong the life span of animals. Some possible geroprotectors include melatonin, carnosine, metformin, rapamycin, nicotinamide mononucleotide (NMN), delta sleep-inducing peptide,glycine, and psilocin. Geroprotectors could belong to multiple classes, depending on which of the hallmarks of aging they influence. The distinction between geroprotectors and senotherapeutics is an evolving area of aging research. Geroprotectors broadly aim to target multiple mechanisms of aging, prolonging lifespan and healthspan by addressing the fundamental causes of aging. Senotherapeutics, on the other hand, are a subset of therapies that specifically target senescent cells, which are dysfunctional cells that accumulate with age and contribute to inflammation and age-related diseases.
transcript of unknown function (TUF) Any RNA transcript whose function is unclear. Such transcripts may include functional non-coding RNAs which have not yet been studied in detail as well as spurious transcripts without any definite function. The DNA sequences from which TUFs are transcribed are generally located in intergenic or intronic regions of the genome. See also junk RNA.
Medical devices: Using single wall carbon nanotubes in medical devices results in no skin contamination, high flexibility, and softness, which are crucial for healthcare applications. Wearable electronics and 5G/6G communication: Electrodes with single wall carbon nanotubes (SWCNTs) exhibit excellent electrochemical properties and flexibility. Bitumen and asphalt: The world's first test section of road pavement with single wall carbon nanotubes (SWCNTs) showed a 67% increase in resistance to cracks and ruts, increasing the lifespan of the materials. Nanocomposites for aviation, automotive, and renewable energy markets: Modifying resin with just 0.02% single wall carbon nanotubes (SWCNTs) increases electrical conductivity by 276% without compromising the mechanical properties of fiber-reinforced polymers, also improving flexural properties and delaying thermal degradation. Additive manufacturing: single wall carbon nanotubes (SWCNTs) are mixed with a suitable printing medium or used as a filler material in the printing process, creating complex structures with enhanced mechanical and electrical properties. Utilizing carbon nanotubes as the channel material of carbon nanotube field-effect transistors. Using carbon nanotubes as a scaffold for diverse microfabrication techniques. Energy dissipation in self-organized nanostructures under the influence of an electric field. Using carbon nanotubes for environmental monitoring due to their active surface area and their ability to absorb gases. Jack Andraka used carbon nanotubes in his pancreatic cancer test.
Stephanie Kate Howard, Moves and Operations Manager, Buckingham Palace Re-servicing Programme, Royal Household. Adelaide Georgina Gray Izat, Paintings Conservator, Royal Collection, Royal Household. Daniel James Kevin Johnson, Archbishop of Canterbury's Coronation Planning Director, on the occasion of the Coronation of Their Majesties The King and The Queen. Kevin Malkin, Detective Constable, Metropolitan Police Service. For services to Royalty Protection. Louise Michelle Walker-Pickett, Purchasing and Cost Control Co- ordinator, Royal Household. Nicola Jane Pritchard, Property Project Manager, Windsor Castle. Warrant Officer Class 1 David Alexander Roper, Grenadier Guards, 25131200; Superintending Clerk, Household Division, on the occasion of the Coronation of Their Majesties The King and The Queen. Warrant Officer Class 2 Julian Philip Desmond Sandford, Royal Corps of Army Music, 25152991; Sergeant Major, Band of the Household Cavalry, on the occasion of the Coronation of Their Majesties The King and The Queen. Christopher Charles Savage, lately Messenger Sergeant Major, The King's Body Guard of the Yeomen of the Guard. Derrick Andrew Scott, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Thomas Nicholas McKinlay Service, lately Acting Chief Operating Officer, Household of The Prince and Princess of Wales. Elizabeth Fiona St Clair, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Kathryn Elizabeth Stone, Paper Conservator, Royal Collection, Royal Household.
Sources: en.wikipedia.org
Bears living in areas near human settlements or around a considerable influx of recreational human activity often come to rely on foods inadvertently provided by humans, especially during summertime. These include refuse, birdseed, agricultural products and honey from apiaries. The majority of the animal portion of their diet consists of insects, such as bees, yellow jackets, ants, beetles and their larvae. American black bears are also fond of honey and will gnaw through trees if hives are too deeply set into the trunks for them to reach it with their paws. Once the hive is breached, the bears will scrape the honeycombs together with their paws and eat them, regardless of stings from the bees. Bears that live in northern coastal regions (especially the Pacific Coast) will fish for salmon during the night, as their black fur is easily spotted by salmon in the daytime. Other bears, such as the white-furred Kermode bears of the islands of western Canada, have a 30% greater success rate in catching salmon than their black-furred counterparts. Other fish, including suckers, trout and catfish, are readily caught whenever possible. Although American black bears do not often engage in active predation of other large animals for much of the year, the species will regularly prey on mule and white-tailed deer fawns in spring, given the opportunity. Bears may catch the scent of hiding fawns when foraging for something else and then sniff them out and pounce on them. As the fawns reach 10 days of age, they can outmaneuver the bears, and their scent is soon ignored until the next year.
Thus, the person's blood clots too readily, and he is perpetually at an increased risk for thrombosis. Individuals heterozygous for the Factor VLeiden mutation carry a risk of venous thrombosis 5–7 times higher than in the general population. Homozygous subjects have a risk 80 times higher. This mutation is also the most common hereditary risk for venous thrombosis among Caucasians. Around 5% of APC resistance are not associated with the above mutation and Factor VLeiden. Other genetic mutations cause APC resistance, but none to the extent that Factor VLeiden does. These mutations include various other versions of Factor V, spontaneous generation of autoantibodies targeting Factor V, and dysfunction of any of APC's cofactors. Also, some acquired conditions may reduce the efficacy of APC in performing its anticoagulative functions. Studies suggest that between 20% and 60% of thrombophilic patients suffer from some form of APC resistance. Warfarin necrosis is an acquired protein C deficiency due to treatment with warfarin, which is a vitamin K antagonist and an anticoagulant itself. However, warfarin treatment may produce paradoxical skin lesions similar to those seen in purpura fulminans. A variant of this response presents as venous limb gangrene when warfarin is used to treat deep vein thrombosis associated with cancer. In these situations, warfarin may be restarted at a low dosage to ensure that the protein C deficiency does not present before the vitamin K coagulation factors II, IX and X are suppressed.
The drug testing policy hampered the quality of the 1992 championship, while attempts to increase interest by hiring WCW wrestler Lex Luger as a figurehead (hosting a WBF television program on USA Network, and planning to make a guest pose during the 1992 championship before being injured in a motorcycle accident) and attempting to sign Lou Ferrigno (who left the organization shortly after the drug testing policy was announced) did not come to fruition. The second PPV received a minuscule audience, and the WBF dissolved only one month later in July 1992.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.